Abstract
Purpose: To analyze corneal biomechanical properties in aspirin users using an ocular response analyzer. Methods: This study included 80 eyes of 40 aspirin users and 80 eyes of 40 individuals who did not use aspirin. Corneal hysteresis (CH), the corneal resistance factor (CRF), Goldman-correlated intraocular pressure (IOPg), and corneal compensated intraocular pressure (IOPcc) were measured in all participants. The independent samples t test was used to compare measurements in the aspirin users and nonusers in the total study population, and in the diabetic patient subgroup. Pearson's correlation analysis was used to examine the relationship between the measured variables in the aspirin users and nonusers. Results: Aspirin users (59.08 ± 11.83 years) were older than nonusers (39.82 ± 12.97 years; p < 0.001). The mean CH was significantly lower in the aspirin user group than in the nonuser group (p = 0.013). Mean IOPg and mean IOPcc were also significantly higher in the aspirin user group (p = 0.027 and p = 0.002, respectively). The mean CRF was lower in the aspirin user group, but not significantly (p = 0.70). There was a positive correlation between CH and CRF (r = 0.767, p < 0.001), and between CRF and IOPg (r = 0.680, p < 0.001), and a negative correlation between CH and IOPcc (r = -0.415, p < 0.001). Conclusions: Aspirin should be taken into account when interpreting the results of corneal biomechanical measurements.
References
1.
Hayden M, Pignone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services task force. Ann Intern Med 2002;136:161-172.
2.
Colwell JA: Aspirin therapy in diabetes. Diabetes Care 1997;20:1767-1771.
3.
Hadley J, Malik N, Meek K: Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking. Micron 2001;32:307-315.
4.
Elsheikh A, Wang D, Brown M, Rama P, Campanelli M, Pye D: Assessment of corneal biomechanical properties and their variation with age. Curr Eye Res 2007;32:11-19.
5.
Stitt AW: The Maillard reaction in eye diseases. Ann NY Acad Sci 2005;1043:582-597.
6.
Kopito R, Gaujoux T, Montard R, Touzeau O, Allouch C, Borderie V, Laroche L: Reproducibility of viscoelastic property and intraocular pressure measurements obtained with the ocular response analyzer. Acta Ophthalmol 2011;89:e225-e230.
7.
Luce DA: Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. J Cataract Refract Surg 2005;31:156-162.
8.
Glass DH, Roberts CJ, Litsky AS, Weber PA: A viscoelastic biomechanical model of the cornea describing the effect of viscosity and elasticity on hysteresis. Invest Ophthalmol Vis Sci 2008;49:3919-3926.
9.
Touboul D, Roberts C, Kerautret J, Garra C, Maurice-Tison S, Saubusse E, Colin J: Correlations between corneal hysteresis, intraocular pressure, and corneal central pachymetry. J Cataract Refract Surg 2008;34:616-622.
10.
Ihanamaki T, Pelliniemi LJ, Vuorio E: Collagens and collagen-related matrix components in the human and mouse eye. Prog Ret Eye Res 2004;23:403-434.
11.
Meek KM, Fullwood NJ: Corneal and scleral collagens - a microscopist's perspective. Micron 2001;32:261-272.
12.
Muller LJ, Pels E, Vrensen GF: The specific architecture of the anterior stroma accounts for maintenance of corneal curvature. Br J Ophthalmol 2001;85:437-443.
13.
Nedic O, Rattan SI, Grune T, Trougakos IP: Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. Free Radic Res 2013;47(suppl 1):28-38.
14.
Sady C, Khosrof S, Nagaraj R: Advanced Maillard reaction and crosslinking of corneal collagen in diabetes. Biochem Biophys Res Commun 1995;214:793-797.
15.
Malik NS, Moss SJ, Ahmed N, Furth AJ, Wall RS, Meek KM: Ageing of the human corneal stroma: structural and biochemical changes. Biochim Biophys Acta 1992;1138:222-228.
16.
Moreno-Montanes J, Maldonado MJ, Garcia N, Mendiluce L, Garcia-Gomez PJ, Segui-Gomez M: Reproducibility and clinical relevance of the ocular response analyzer in nonoperated eyes: corneal biomechanical and tonometric implications. Invest Ophthalmol Vis Sci 2008;49:968-974.
17.
Malik NS, Meek KM: Vitamins and analgesics in the prevention of collagen ageing. Age Ageing 1996;25:279-284.
18.
Malik NS, Meek KM: The inhibition of sugar-induced structural alterations in collagen by aspirin and other compounds. Biochem Biophys Res Commun 1994;199:683-686.
19.
Kaji Y, Usui T, Oshika T, Matsubara M, Yamashita H, Araie M, Murata T, Ishibashi T, Nagai R, Horiuchi S, Amano S: Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 2000;41:362-368.
20.
Hager A, Wegscheider K, Wiegand W: Changes of extracellular matrix of the cornea in diabetes mellitus. Graefes Arch Clin Exp Ophthalmol 2009;247:1369-1374.
21.
Goldich Y, Barkana Y, Gerber Y, Rasko A, Morad Y, Harstein M, Avni I, Zadok D: Effect of diabetes mellitus on biomechanical parameters of the cornea. J Cataract Refract Surg 2009;35:715-719.
22.
Sahin A, Bayer A, Ozge G, Mumcuoglu T: Corneal biomechanical changes in diabetes mellitus and their influence on intraocular pressure measurements. Invest Ophthalmol Vis Sci 2009;50:4597-4604.
23.
Scheler A, Spoerl E, Boehm AG: Effect of diabetes mellitus on corneal biomechanics and measurement of intraocular pressure. Acta Ophthalmol 2012;90:e447-e451.
24.
Roy R, Boskey AL, Bonassar LJ: Non-enzymatic glycation of chondrocyte-seeded collagen gels for cartilage tissue engineering. J Orthop Res 2008;26:1434-1439.
25.
Kotecha A, Oddone F, Sinapis C, Elsheikh A, Sinapis D, Sinapis A, Garway-Heath DF: Corneal biomechanical characteristics in patients with diabetes mellitus. J Cataract Refract Surg 2010;36:1822-1828.
26.
Kida T, Liu JH, Weinreb RN: Effects of aging on corneal biomechanical properties and their impact on 24-hour measurement of intraocular pressure. Am J Ophthalmol 2008;146:567-572.
27.
Kotecha A, Elsheikh A, Roberts CR, Zhu H, Garway-Heath DF: Corneal thickness- and age-related biomechanical properties of the cornea measured with the ocular response analyzer. Invest Ophthalmol Vis Sci 2006;47:5337-5347.
28.
Kamiya K, Shimizu K, Ohmoto F: Effect of aging on corneal biomechanical parameters using the ocular response analyzer. J Refract Surg 2009;25:888-893.
29.
Ortiz D, Pinero D, Shabayek MH, Arnalich-Montiel F, Alio JL: Corneal biomechanical properties in normal, post-laser in situ keratomileusis, and keratoconic eyes. J Cataract Refract Surg 2007;33:1371-1375.
30.
Narayanaswamy A, Chung RS, Wu RY, Park J, Wong WL, Saw SM, Wong TY, Aung T: Determinants of corneal biomechanical properties in an adult Chinese population. Ophthalmology 2011;118:1253-1259.
31.
Kamiya K, Hagishima M, Fujimura F, Shimizu K: Factors affecting corneal hysteresis in normal eyes. Graefes Arch Clin Exp Ophthalmol 2008;246:1491-1494.
32.
Broman AT, Congdon NG, Bandeen-Roche K, Quigley HA: Influence of corneal structure, corneal responsiveness, and other ocular parameters on tonometric measurement of intraocular pressure. J Glaucoma 2007;16:581-588.
33.
Mangouritsas G, Morphis G, Mourtzoukos S, Feretis E: Association between corneal hysteresis and central corneal thickness in glaucomatous and non-glaucomatous eyes. Acta Ophthalmol 2009;87:901-905.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
